24 Mar 2016
Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name ‘Oxra’
Sun Pharma and AstraZeneca Pharma India announced a partnership for the distribution of dapagliflozin, an innovative Type II diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.
Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name ‘Oxra’. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.
Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name ‘Oxramet’, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.
Licensing plays a vital role in pharmaceutical industry. Previously Gilead Sciences entered into licensing agreements with seven Indian generic manufacturers – Cipla, Cadila Healthcare, Hetero, Strides Arcolab, Ranbaxy, Sequent Scientific and Mylan. This license allows the companies to manufacture and sell the drug in any of the 91 voluntary licence (VL) countries at their own price but at a 7% royalty rate on any sales. Gliead was not having field promotion team, therefore licenses to other companies.
Here in this dapagliflozin deal, Astrazeneca will market the product in India in brand name Forxiga, at the same time license given to Sun Pharma to market the dapagliflozin in another brand name. For Sun Pharma, dapagliflozin will help to enhance the diabetic portfolio.